← Browse by Condition
Medical Condition

graft failure

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2, Phase 2

ClinicalMetric tracks all active clinical trials for graft failure sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — graft failure Clinical Trials

How many clinical trials are currently recruiting for graft failure?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for graft failure, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for graft failure?
graft failure research spans Phase 1 (1 trial), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a graft failure clinical trial?
Eligibility criteria for graft failure trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
2
Top Sponsors
University of Edinburgh 1 trial
Amsterdam UMC, location VUmc 1 trial
Arkansas Children's Hospital Research Institute 1 trial
Masonic Cancer Center, University of Minnesota 1 trial

Recruiting Clinical Trials

NCT06800430
Recruiting
Graft Failure and Consequences of Coronary Artery Bypass Graft Surgery
Enrollment
70 pts
Location
United Kingdom
Sponsor
University of Edinburgh
View Trial →
NCT04772768
Recruiting
Prior CABG Patients Evaluated for Saphenous VeIn grAft DysfUnction and Progression of Coronary arTery Disease
Enrollment
500 pts
Location
Netherlands
Sponsor
Amsterdam UMC, location VUmc
View Trial →
NCT07252050 Phase 1, Phase 2
Recruiting
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
Enrollment
24 pts
Location
United States
Sponsor
Arkansas Children's Hospital R...
View Trial →
NCT06872333 Phase 2
Recruiting
Allo HSCT for High Risk Hemoglobinopathies
Enrollment
62 pts
Location
United States
Sponsor
Masonic Cancer Center, Univers...
View Trial →

Related Conditions

sickle cell disease (2) coronary artery bypass (1) coronary artery bypass graft (1) coronary artery bypass graft surgery cabg (1) recurrent angina after coronary artery bypass graft (1) coronary artery disease progression (1) hematopoetic stem cell transplant (1) haploidentical hematopoietic stem cell transplant (1) haploidentical stem cell transplantation (1) hemoglobinopathies (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology